[PDF][PDF] A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors

M Friedlander, T Meniawy, B Markman… - J Clin …, 2017 - beigenemedical.com
M Friedlander, T Meniawy, B Markman, LR Mileshkin, PR Harnett, M Millward, J Lundy…
J Clin Oncol, 2017beigenemedical.com
BACKGROUND METHODS RESULTS CONCLUSIONS Page 1 BACKGROUND Several
reports describe a direct link between DNA damage and the upregulation of ligands that
activate natural killer (NK) and T-cell-mediated immune responses Upregulation of tumor-associated
antigens with PARP inhibitors may improve the antitumor activity of checkpoint inhibitors
BGB-A317, a humanized IgG4 variant monoclonal antibody with no Fc gamma receptor
binding, targets the programmed cell death-1 (PD-1) receptor and is being developed for the …
BACKGROUND
Several reports describe a direct link between DNA damage and the upregulation of ligands that activate natural killer (NK) and T-cell-mediated immune responses
beigenemedical.com